Chronic obstructive pulmonary disease (COPD) remains a significant area of unmet medical need. It is a progressive and irreversible lung disease that restricts breathing.
Daxas (Roflumilast) is a phosphodiesterase-4 (PDE4) inhibitor that is being developed to treat the underlying inflammation in COPD and related inflammatory diseases. It could be both the first PDE4 inhibitor and the first orally administered anti-inflammatory treatment for COPD patients. As a once-daily, non-steroidal anti-inflammatory treatment, Daxas offers the opportunity for a new approach to the treatment of COPD.
I. Presentation - General Information
II. Asthma and Chronic Obstructive Pulmonary Disease (COPD)
New Treatments For COPD
III. Originators - In-Licensers - Partners
V. Clinical Trials
VI. SWOT Analysis
|Publication date:||Number of pages:||Price:|